Compare ACADIA Pharmaceuticals Inc. (ACAD) vs LYFT Inc (LYFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs LYFT Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.72 (market cap $4.49B), while LYFT Inc trades at $15.02 (market cap $5.86B). The key difference: LYFT Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | LYFT | |
|---|---|---|
Market Cap | $4.49B | $5.86B |
Sector | Health | Industrials |
52-Week High | $28.06 | $24.57 |
52-Week Low | $20.06 | $12.65 |
Enterprise Value | $3.69B | $5.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Lyft trades at $15.44, up 0.46% today, with a bullish technical signal from moving averages and oscillators. The company shows strong profitability with 43.82% net income margin and robust cash flow generation of $1.17B from operations in 2025. Recent management changes include the appointment of Senthil Padmanabhan as CTO effective July 2026, signaling continued operational focus.
Lyft presents an attractive valuation with P/E of 2.25 and P/S of 0.97, trading below the $18.25 consensus price target. However, mixed earnings performance and competitive pressures from Uber require monitoring. The stock offers upside potential but faces execution risks in the evolving ridesharing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
